IONS
Ionis Pharmaceuticals, Inc.
49.49
USD
This page is just a preview of the data found in TrendSpider’s full version
Ionis Pharmaceuticals, Inc. stock is up 11.79% since 30 days ago. The next earnings date is Feb 21, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 62.5% of the previous 7 November’s closed higher than October. In the last 8 Unusual Options Trades, there were 1 PUT, 7 CALLs. 34% of analysts rate it a buy.
| Date & Time | Expiration Date | Strike Price | Trade Type | Size | Open Interest |
|---|---|---|---|---|---|
| 23 Oct 16:59 | 15 Dec, 2023 | 45.00 | 355 | ||
| 14 Nov 16:34 | 15 Dec, 2023 | 50.00 | 999 | ||
| 14 Nov 16:43 | 15 Dec, 2023 | 50.00 | 999 | ||
| 14 Nov 19:36 | 19 Apr, 2024 | 52.50 | 116 | ||
| 14 Nov 20:46 | 15 Dec, 2023 | 50.00 | 999 | ||
| 16 Nov 19:12 | 19 Jan, 2024 | 52.50 | 24 | ||
| 16 Nov 19:15 | 19 Jan, 2024 | 52.50 | 24 | ||
| 28 Nov 18:33 | 15 Dec, 2023 | 50.00 | 2018 |
Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an injection for the treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; WAYLIVRA, a treatment for familial chylomicronemia syndrome and familial partial lipodystrophy.
